Stem Cells for Retinal Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on immunosuppressive therapy.
What data supports the effectiveness of the treatment CD34+ bone marrow stem cells for retinal disease?
Is the use of CD34+ bone marrow stem cells for retinal disease safe?
Preliminary findings from a phase 1 clinical trial suggest that using CD34+ bone marrow stem cells for retinal conditions is generally safe, as these cells help repair damaged tissue. However, there have been reports of serious complications, such as retinal detachments, with other types of stem cell treatments, highlighting the importance of conducting these treatments under proper medical supervision.26789
How is the CD34+ bone marrow stem cell treatment different from other treatments for retinal disease?
The CD34+ bone marrow stem cell treatment is unique because it involves injecting stem cells directly into the eye to help repair damaged retinal tissue, which is different from other treatments that may not directly target tissue repair. This approach uses the body's own cells to potentially slow down or reverse retinal damage, offering a novel method compared to traditional therapies.2481011
What is the purpose of this trial?
This trial is testing if injecting special cells from bone marrow into the eye is safe and possible for patients who are permanently blind due to retinal diseases. The hope is that these cells can help fix the damaged parts of their eyes.
Research Team
Susanna s Park, MD PhD
Principal Investigator
University of California Davis Eye Center
Eligibility Criteria
This trial is for adults over 18 with vision loss from conditions like macular degeneration or diabetic retinopathy. Participants must have a visual acuity ranging from 20/100 to hand movement and the affected eye should be the one with worse vision. They shouldn't have had certain eye treatments in the last 6 months, no blood disorders, active diseases, or be on immunosuppressive therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Intravitreal injection of autologous CD34+ stem cells isolated from bone marrow aspirate
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CD34+ bone marrow stem cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Davis
Lead Sponsor